Plus therapeutics announces peer-reviewed publication in nature communications highlighting promising phase 1 results for rhenium (186re) obisbemeda in glioblastoma

Rhenium ( 186 re) obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (gbm) patients patients receiving >100 gy of rhenium ( 186 re) obisbemeda achieved a median overall survival of 17 months, more than double the 8-month median overall survival with standard of care houston, march 07, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announces the publication of results in a peer-reviewed manuscript titled, "treatment of recurrent glioma by rhenium (186re) obisbemeda (186rnl): a phase 1 clinical trial" in the peer-reviewed medical journal nature communications. “peer-reviewed publication of our phase 1 glioma data in a prestigious, high-impact factor journal is substantial validation for this important clinical program,” said marc h.
PSTV Ratings Summary
PSTV Quant Ranking